共载阿霉素和依克立达的PLGA纳米粒的制备及表征

陈大中; 高洁; 解方园; 张翮; 鲁莹; 邹豪; 钟延强

doi:10.3969/j.issn.1006-0111.2017.03.007

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强

文章导航 > 药学实践与服务 > 2017 > 35(3): 219-223,251

陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强. 共载阿霉素和依克立达的PLGA纳米粒的制备及表征[J]. 药学实践与服务, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007

引用本文:

CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007

Citation:

CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

doi: 10.3969/j.issn.1006-0111.2017.03.007

第二军医大学药学院, 上海 200433

基金项目: 国家自然科学基金资助项目（81573376）

Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 目的建立药物测定方法，并制备共载阿霉素和依克立达的PLGA纳米粒。方法利用紫外分光光度法（UV）和高效液相色谱法（HPLC）分别建立阿霉素和依克立达的测定方法；采用纳米沉淀法制备共载纳米粒，通过调节两药的投药比，优化处方，考察纳米粒的粒径、形态、包封率、载药量以及体外释放。结果阿霉素在1~40 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=0.021C+0.002，r=0.999 5；依克立达在0.5~100 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=120 742.462 6C+1 974.570 4，r=1.000 0；通过处方优化，共载纳米粒的粒径约为50 nm，分布均一，呈圆形，阿霉素和依克立达的包封率分别为56.58%、51.66%，载药量分别为1.48%、1.85%，两药摩尔比约为1：1；体外释放缓慢。结论分别建立了方便快捷、结果准确、重复性好的阿霉素和依克立达的检测方法，并且制备了分散性好、粒径较小的纳米粒，为后续实验提供基础。
- 阿霉素 /
- 依克立达 /
- 纳米粒 /
- 紫外分光光度法 /
- 高效液相色谱法
Abstract: Objective To establish methods for the determination of doxorubicin and elacridar, and prepare PLGA nanoparticles for the co-delivery of doxorubicin and elacridar. Methods Ultraviolet spectrophotometry (UV) and high performance liquid chromatography (HPLC) were used to establish the determination method of doxorubicin and elacridar, respectively; co-delivery nanoparticles system was prepared by nanoprecipitation method, and optimizing the prescription was by adjusting the dosage ratio of the two drugs to investigate the particle size,morphology, encapsulation efficiency (EE), drug loading (DL) and in vitro release. Results The linearity of doxorubicin was better in the rang of 1 to 40 μg/ml, A=0.021C+0.002,r=0.999 5;the linearity of elacridar was better in the rang of 0.5 to 100 μg/ml,A=120 742.462 6C+1 974.570 4,r=1.000 0;the particle size was about 50 nm; transmission electron microscope (TEM) showed that nanoparticles were round in shape and had a good dispersion;EE of doxorubicin and elacridar were 56.58%、51.66%,respectively, DL of doxorubicin and elacridar were 1.48%、1.85%,respectively,the molar ratio of two drugs was about 1:1;the nanoparticles released slowly in vitro. Conclusion The established methods of doxorubicin and elacridar were convenient and efficient, accurate and repeatable.The Co-delivery nanoparticles system was well dispersionand smaller size, which could be used for further studies.
- doxorubicin /
- elacridar /
- nanoparticles /
- UV /
- HPLC

[1]	Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001,414(6859):105-111.
[2]	Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138(4):645-659.
[3]	Cojoc M, Mäbert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms[J]. Semin Cancer Biol, 2014, 31:16-27.
[4]	Hubensack M, Müller C, Höcherl P, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice[J]. J Cancer Res Clin Oncol, 2008, 134(5): 597-607.
[5]	Karla PK, Earla R, Boddu SH, et al. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells[J]. Curr Eye Res, 2009, 34(1): 1-9.
[6]	Nieto Montesinos RM, Beduneau A, Lamprecht A, et al. Liposomes co-loaded with elacridar and tariquidar to modulate the P-glycoprotein at the blood-brain barrier[J]. Mol Pharm, 2015, 12(11):3829-3838.
[7]	Wong HL, Bendayan R, Rauth AM, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer[J]. J Control Release, 2006, 116(3):275-284.
[8]	Singh MS, Lamprecht A. Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin[J]. Int J Pharm, 2015, 478(2):745-752.
[9]	Planting AST,Sonneveld P,Gaast AVD,et al.A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2005,55(1):91-99.
[10]	Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery[J]. Biomaterials, 2007, 28(5):869-876.
[11]	Zhu H, Chen H, Zeng X, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance[J]. Biomaterials, 2013, 35(7):2391-2400.

[1]	孙雨菡, 许子艺, 廖峻, 张翮, 樊莉, 鲁莹. HPLC法同时测定盐酸阿霉素与氯尼达明的含量 . 药学实践与服务, 2024, 42(3): 127-130. doi: 10.12206/j.issn.2097-2024.202306043
[2]	许子艺, 孙雨菡, 樊莉, 卢光照, 张鹰楠, 张翮. 载阿霉素金纳米粒的制备和细胞毒性研究 . 药学实践与服务, 2024, 42(2): 73-77, 81. doi: 10.12206/j.issn.2097-2024.202308043
[3]	秦烨, 丁欣, 张雅. 参附汤抗阿霉素心肌病小鼠血清代谢组学研究 . 药学实践与服务, 2022, 40(2): 108-112. doi: 10.12206/j.issn.1006-0111.202105116
[4]	满缓, 张凤, 黄豆豆, 熊筱娟, 詹勤, 廖丽娜, 李铁军, 陈万生. 升陷汤及各单味药对阿霉素致心肌细胞损伤的保护作用 . 药学实践与服务, 2019, 37(4): 304-308. doi: 10.3969/j.issn.1006-0111.2019.04.004
[5]	杨丽娜, 曾棋平, 曹毅祥, 蔡小辉, 陈锦珊. 双波长高效液相色谱法同时测定复方首乌藤合剂中7种有效成分 . 药学实践与服务, 2018, 36(4): 334-337. doi: 10.3969/j.issn.1006-0111.2018.04.010
[6]	周倩, 刘奎, 马静, 谭光国. 芪附汤对大鼠抗阿霉素心脏毒性作用的血清气相色谱-质谱代谢组学研究 . 药学实践与服务, 2018, 36(4): 313-317. doi: 10.3969/j.issn.1006-0111.2018.04.006
[7]	朱冰, 盛丹丹, 李善心, 张黎. 盐霉素纳米制剂的研究进展 . 药学实践与服务, 2016, 34(6): 489-492,515. doi: 10.3969/j.issn.1006-0111.2016.06.003
[8]	邵帅, 崔光华, 周旭, 高钟镐, 黄伟. 中心组合设计法优化载基因壳聚糖纳米粒的最佳转染制备区域 . 药学实践与服务, 2014, 32(6): 419-424. doi: 10.3969/j.issn.1006-0111.2014.06.006
[9]	马建丽, 刘皈阳, 李翔, 黄欣欣, 姚飞, 马晓晖. 高效液相色谱法同时测定扁咽口服液中黄芩苷和肉桂酸的含量 . 药学实践与服务, 2013, 31(6): 451-453. doi: 10.3969/j.issn.1006-0111.2013.06.015
[10]	王灵霞, 朱东亮, 柴逸峰. 高效液相色谱法同时测定3种不同剂型六味地黄丸中4种成分的含量 . 药学实践与服务, 2013, 31(4): 296-299. doi: 10.3969/j.issn.1006-0111.2013.04.016
[11]	张明媛, 常靓, 刘长海, 陈秋芬, 张军东, 陆峰. 柱前衍生化高效液相色谱法检测硫酸阿米卡星注射液中卡那霉素含量的改进 . 药学实践与服务, 2013, 31(5): 344-346. doi: 10.3969/j.issn.1006-0111.2013.05.006
[12]	许洁, 王菊, 冯年平, 赵继会, 于燕燕, 谭蓉. 星点设计-效应面法优化冬凌草甲素聚乳酸纳米粒的制备工艺 . 药学实践与服务, 2009, 27(5): 345-348,369.
[13]	刘海英, 杨宁, 黄力, 沈振华, 苏芳. 高效液相色谱法测定氯霉素醇溶液中氯霉素的含量 . 药学实践与服务, 2008, (4): 289-290,293.
[14]	谭生建, 刘刚, 张捷, 刘昌叶, 潘敏翔, 常华. 高效液相色谱法同时测定银黄口服液中绿原酸和黄芩苷含量 . 药学实践与服务, 2008, (2): 138-140.
[15]	程颖, 濮存海, 吴爱兰, 王波. 高效液相色谱法测定阿立哌唑片剂的含量 . 药学实践与服务, 2005, (5): 297-299.
[16]	罗虹, 王晓玲, 李玉兰. 紫外分光光度法测定甲砜霉素胶囊的含量 . 药学实践与服务, 2002, (2): 101-102.
[17]	李伊庆, 王海燕, 姜宗文. 旋光法和紫外分光光度法测定卡地滴眼液含量 . 药学实践与服务, 2002, (3): 174-176.
[18]	牟冰, 徐贵丽, 彭显平, 杨艳, 方丽莎. 格拉司琼与阿霉素、表阿霉素配伍的相互作用研究 . 药学实践与服务, 2002, (1): 17-18.
[19]	徐敏, 黄德华. 紫外分光光度法和旋光法分别测定呋麻滴鼻剂中两组分的含量 . 药学实践与服务, 1998, (3): 170-172.
[20]	谷根妹, 樊效琪. 紫外分光光度法测定达那唑栓剂的含量 . 药学实践与服务, 1995, (4): 229-231.

点击查看大图

计量

文章访问数: 2503
HTML全文浏览量: 305
PDF下载量: 1244
被引次数: 0

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

doi: 10.3969/j.issn.1006-0111.2017.03.007

第二军医大学药学院, 上海 200433

基金项目: 国家自然科学基金资助项目（81573376）

收稿日期: 2017-01-18
修回日期: 2017-03-31

关键词:

阿霉素 /

依克立达 /

纳米粒 /

紫外分光光度法 /

高效液相色谱法

摘要: 目的建立药物测定方法，并制备共载阿霉素和依克立达的PLGA纳米粒。方法利用紫外分光光度法（UV）和高效液相色谱法（HPLC）分别建立阿霉素和依克立达的测定方法；采用纳米沉淀法制备共载纳米粒，通过调节两药的投药比，优化处方，考察纳米粒的粒径、形态、包封率、载药量以及体外释放。结果阿霉素在1~40 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=0.021C+0.002，r=0.999 5；依克立达在0.5~100 μg/ml浓度范围内线性关系良好，标准曲线回归方程为A=120 742.462 6C+1 974.570 4，r=1.000 0；通过处方优化，共载纳米粒的粒径约为50 nm，分布均一，呈圆形，阿霉素和依克立达的包封率分别为56.58%、51.66%，载药量分别为1.48%、1.85%，两药摩尔比约为1：1；体外释放缓慢。结论分别建立了方便快捷、结果准确、重复性好的阿霉素和依克立达的检测方法，并且制备了分散性好、粒径较小的纳米粒，为后续实验提供基础。

English Abstract

Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2017-01-18
Rev Recd Date: 2017-03-31

Keywords:

doxorubicin /
elacridar /
nanoparticles /
UV /
HPLC

Abstract: Objective To establish methods for the determination of doxorubicin and elacridar, and prepare PLGA nanoparticles for the co-delivery of doxorubicin and elacridar. Methods Ultraviolet spectrophotometry (UV) and high performance liquid chromatography (HPLC) were used to establish the determination method of doxorubicin and elacridar, respectively; co-delivery nanoparticles system was prepared by nanoprecipitation method, and optimizing the prescription was by adjusting the dosage ratio of the two drugs to investigate the particle size,morphology, encapsulation efficiency (EE), drug loading (DL) and in vitro release. Results The linearity of doxorubicin was better in the rang of 1 to 40 μg/ml, A=0.021C+0.002,r=0.999 5;the linearity of elacridar was better in the rang of 0.5 to 100 μg/ml,A=120 742.462 6C+1 974.570 4,r=1.000 0;the particle size was about 50 nm; transmission electron microscope (TEM) showed that nanoparticles were round in shape and had a good dispersion;EE of doxorubicin and elacridar were 56.58%、51.66%,respectively, DL of doxorubicin and elacridar were 1.48%、1.85%,respectively,the molar ratio of two drugs was about 1:1;the nanoparticles released slowly in vitro. Conclusion The established methods of doxorubicin and elacridar were convenient and efficient, accurate and repeatable.The Co-delivery nanoparticles system was well dispersionand smaller size, which could be used for further studies.

引用本文:

Citation:

CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007